Last 12 months
Inside the activity.
9 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 3 | 0 |
| Mar 2026 | 6 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2019 Filed Jun 11, 2019 23:07 UTC |
Pay Paul WilliamDirector
|
GrantStock Option (right to buy) · Derivative | 30,579 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001778480-19-000002 · primary_doc.xml · derivative · entry 1 Pay Paul William · CIK 0001778480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,579 Underlying: Common Shares · 30,579 shares Expires 2027-09-26 F4 · derivative.exercise_price: In Canadian currency. F1 · shares: On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa. F2 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F3 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on 9/26/18, and monthly thereafter through 9/26/20. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:58 UTC |
Nijhawan PardeepDirector · Chief Executive Officer · 10% owner
|
GrantStock Option (right to buy) · Derivative | 1,529 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001777962-19-000002 · primary_doc.xml · derivative · entry 5 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,529 Underlying: Common Shares · 1,529 shares Expires 2028-12-28 F4 · derivative.exercise_price: In Canadian currency. F2 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F5 · shares: This option was issued in replacement of an option to purchase shares of Edesa. F7 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on 12/28/19, and monthly thereafter through 12/28/21. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:58 UTC |
Nijhawan PardeepDirector · Chief Executive Officer · 10% owner
|
GrantStock Option (right to buy) · Derivative | 44,823 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001777962-19-000002 · primary_doc.xml · derivative · entry 4 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,823 Underlying: Common Shares · 44,823 shares Expires 2027-09-26 F4 · derivative.exercise_price: In Canadian currency. F2 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F5 · shares: This option was issued in replacement of an option to purchase shares of Edesa. F6 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on 9/26/18, and monthly thereafter through 9/26/20. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:58 UTC |
Nijhawan PardeepDirector · Chief Executive Officer · 10% owner
|
GrantCommon Shares | 211,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001777962-19-000002 · primary_doc.xml · nonDerivative · entry 3 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The Digestive Health Clinic Inc. Disclosed balance after: 211,506 F1 · shares: Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the "Issuer") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. ("Edesa") and the shareholders of Edesa Biotech Inc. F2 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F3 · ownership.nature: Each of Pardeep Nijhawan Medicine Professional Corporation and The Digestive Health Clinic Inc. are wholly-owned by Pardeep Nijhawan. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:58 UTC |
Nijhawan PardeepDirector · Chief Executive Officer · 10% owner
|
GrantCommon Shares | 1,988,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001777962-19-000002 · primary_doc.xml · nonDerivative · entry 2 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Pardeep Nijhawan Medicine Professional Corporation Disclosed balance after: 1,988,424 F1 · shares: Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the "Issuer") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. ("Edesa") and the shareholders of Edesa Biotech Inc. F2 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F3 · ownership.nature: Each of Pardeep Nijhawan Medicine Professional Corporation and The Digestive Health Clinic Inc. are wholly-owned by Pardeep Nijhawan. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:58 UTC |
Nijhawan PardeepDirector · Chief Executive Officer · 10% owner
|
GrantCommon Shares | 507,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001777962-19-000002 · primary_doc.xml · nonDerivative · entry 1 Nijhawan Pardeep · CIK 0001777962 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,129 F1 · shares: Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the "Issuer") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. ("Edesa") and the shareholders of Edesa Biotech Inc. F2 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:22 UTC |
Brooks Michael JPresident
|
GrantStock Option (right to buy) · Derivative | 1,529 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001779126-19-000002 · primary_doc.xml · derivative · entry 3 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,529 Underlying: Common Shares · 1,529 shares Expires 2028-12-28 F1 · derivative.exercise_price: In Canadian currency. F2 · shares: On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa. F3 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F6 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on 12/28/19, and monthly thereafter through 12/28/21. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:22 UTC |
Brooks Michael JPresident
|
GrantStock Option (right to buy) · Derivative | 22,934 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001779126-19-000002 · primary_doc.xml · derivative · entry 2 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,934 Underlying: Common Shares · 22,934 shares Expires 2027-09-26 F1 · derivative.exercise_price: In Canadian currency. F2 · shares: On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa. F3 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F5 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on 9/26/18, and monthly thereafter through 9/26/20. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:22 UTC |
Brooks Michael JPresident
|
GrantStock Option (right to buy) · Derivative | 128,753 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001779126-19-000002 · primary_doc.xml · derivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,753 Underlying: Common Shares · 128,753 shares Expires 2027-08-28 F1 · derivative.exercise_price: In Canadian currency. F2 · shares: On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa. F3 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F4 · derivative.exercise_date: This option was fully vested on 8/28/17. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:52 UTC |
van der Velden PeterDirector · 10% owner
|
GrantCommon Shares | 148,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-030609 · tv523428_4.xml · nonDerivative · entry 2 van der Velden Peter · CIK 0001778046 · Director · 10% owner Lumira Capital Investment Management Inc. · CIK 0001702636 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Lumira Capital II (International), L.P. Disclosed balance after: 148,999 F1 · shares: Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the "Issuer") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. and the shareholders of Edesa Biotech Inc. F3 · shares: All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F2 · ownership.nature: This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ["LCII LP"], (ii) Lumira Capital II (International), L.P. ["LCII INT LP"], (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co. and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc. Lumira GP Holdings Co. and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 21:52 UTC |
van der Velden PeterDirector · 10% owner
|
GrantCommon Shares | 1,611,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-030609 · tv523428_4.xml · nonDerivative · entry 1 van der Velden Peter · CIK 0001778046 · Director · 10% owner Lumira Capital Investment Management Inc. · CIK 0001702636 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Lumira Capital II, L.P. Disclosed balance after: 1,611,338 F1 · shares: Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the "Issuer") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. and the shareholders of Edesa Biotech Inc. F3 · shares: All share numbers reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F2 · ownership.nature: This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ["LCII LP"], (ii) Lumira Capital II (International), L.P. ["LCII INT LP"], (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co. and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc. Lumira GP Holdings Co. and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 19:37 UTC |
Chun PaulDirector
|
GrantShare Option (Right to Buy) · Derivative | 357 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001144204-19-013782 · tv516191_4.xml · derivative · entry 1 Chun Paul · CIK 0001692037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357 Underlying: Common Shares · 357 shares Expires 2026-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:36 UTC |
SAMPAT MAYANK D.Director
|
GrantShare Option (Right to Buy) · Derivative | 357 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001144204-19-013781 · tv516190_4.xml · derivative · entry 1 SAMPAT MAYANK D. · CIK 0001620136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357 Underlying: Common Shares · 357 shares Expires 2026-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:36 UTC |
Aghib Deborah F.Director
|
GrantShare Option (Right to Buy) · Derivative | 357 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001144204-19-013780 · tv516189_4.xml · derivative · entry 1 Aghib Deborah F. · CIK 0001727655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357 Underlying: Common Shares · 357 shares Expires 2026-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 19:37 UTC |
Che Tessie MDirector
|
GrantShare Option (Right to Buy) · Derivative | 357 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001144204-19-013783 · tv516192_4.xml · derivative · entry 1 Che Tessie M · CIK 0001380900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357 Underlying: Common Shares · 357 shares Expires 2026-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:35 UTC |
Olson Charles VDirector
|
GrantShare Option (Right to Buy) · Derivative | 357 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001144204-19-013778 · tv516186_4.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357 Underlying: Common Shares · 357 shares Expires 2026-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 23:36 UTC |
HILL DAVID LOUISDirector
|
GrantShare Option (Right to Buy) · Derivative | 357 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001144204-19-013779 · tv516188_4.xml · derivative · entry 1 HILL DAVID LOUIS · CIK 0001620224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357 Underlying: Common Shares · 357 shares Expires 2026-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020. Read SEC document |
| March 06, 2019 Filed Mar 11, 2019 21:31 UTC |
OAKES FRANK R.Director · President & CEO
|
SaleCommon Shares, without par value | 4,000 | $1.25 | $5,000.40 |
DisclosureSEC source: 0001144204-19-013348 · tv515980_4.xml · nonDerivative · entry 1 OAKES FRANK R. · CIK 0001620188 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,924 F1 · kind: These shares were sold pursuant to a trading plan adopted by the reporting person in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 12, 2018 Filed Oct 13, 2018 01:50 UTC |
MORSE DANIEL E.Former Director
|
SaleCommon Shares, without par value | 7,047 | $1.31 | $9,259.76 |
DisclosureSEC source: 0001144204-18-053713 · tv504785_4.xml · nonDerivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,741 F1 · balance_after: The Issuer completed a 1-for-7 reverse share split of its common shares effective May 4, 2018. The amount stated reflects the post-split adjustment. Fractional shares resulting from the reverse share split were rounded to the nearest whole share. Read SEC document |
| October 12, 2018 Filed Oct 13, 2018 01:49 UTC |
OAKES FRANK R.Director · President & CEO
|
SaleCommon Shares, without par value | 3,000 | $1.31 | $3,930.00 |
DisclosureSEC source: 0001144204-18-053712 · tv504784_4.xml · nonDerivative · entry 1 OAKES FRANK R. · CIK 0001620188 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,924 F1 · kind: These shares were sold pursuant to a trading plan adopted by the reporting person in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: The Issuer completed a 1-for-7 reverse share split of its common shares effective May 4, 2018. The amount stated reflects the post-split adjustment. Fractional shares resulting from the reverse share split were rounded to the nearest whole share. Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 10:11 UTC |
MORSE DANIEL E.Director
|
SaleCommon Shares, without par value | 4,366 | $0.81 | $3,514.63 |
DisclosureSEC source: 0001144204-18-018810 · tv490213_4.xml · nonDerivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 0 Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:21 UTC |
Chun PaulDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014757 · tv488524_4.xml · derivative · entry 1 Chun Paul · CIK 0001692037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:23 UTC |
Che Tessie MDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014760 · tv488526_4.xml · derivative · entry 1 Che Tessie M · CIK 0001380900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:23 UTC |
MORSE DANIEL E.Director
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · derivative · entry 7 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:23 UTC |
MORSE DANIEL E.Director
|
SaleCommon shares, without par value | 3,500 | $0.80 | $2,789.50 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 5 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 4,366 Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:22 UTC |
Aghib Deborah F.Director
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014759 · tv488525_4.xml · derivative · entry 1 Aghib Deborah F. · CIK 0001727655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:21 UTC |
Olson Charles VDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014754 · tv488522_4.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:21 UTC |
HILL DAVID LOUISDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014755 · tv488523_4.xml · derivative · entry 1 HILL DAVID LOUIS · CIK 0001620224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:21 UTC |
SAMPAT MAYANK D.Director
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014753 · tv488521_4.xml · derivative · entry 1 SAMPAT MAYANK D. · CIK 0001620136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:20 UTC |
OAKES FRANK R.Director · President & CEO
|
GrantShare Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014752 · tv488520_4.xml · derivative · entry 1 OAKES FRANK R. · CIK 0001620188 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:20 UTC |
NIFFENEGGER KATHIChief Financial Officer
|
GrantShare Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014750 · tv488519_4.xml · derivative · entry 1 NIFFENEGGER KATHI · CIK 0001620146 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 00:19 UTC |
BAXTER GREGORY T.EVP, Corporate Development
|
GrantShare Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001144204-18-014749 · tv488518_4.xml · derivative · entry 1 BAXTER GREGORY T. · CIK 0001620138 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2025-03-12 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019. Read SEC document |
| March 09, 2018 Filed Mar 15, 2018 00:23 UTC |
MORSE DANIEL E.Director
|
SaleCommon shares, without par value | 7,000 | $0.81 | $5,635.00 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 4 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 7,866 Read SEC document |
| February 28, 2018 Filed Mar 15, 2018 00:23 UTC |
MORSE DANIEL E.Director
|
SaleCommon shares, without par value | 7,000 | $0.79 | $5,530.00 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 3 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 14,866 Read SEC document |
| February 26, 2018 Filed Mar 15, 2018 00:23 UTC |
MORSE DANIEL E.Director
|
SaleCommon shares, without par value | 7,000 | $0.79 | $5,530.00 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 2 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 21,866 Read SEC document |
| February 22, 2018 Filed Mar 15, 2018 00:23 UTC |
MORSE DANIEL E.Director
|
SaleCommon Shares, without par value | 7,800 | $0.78 | $6,115.20 |
DisclosureSEC source: 0001144204-18-014761 · tv488572_4.xml · nonDerivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Joint Account with Spouse Disclosed balance after: 28,866 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 13:46 UTC |
Aghib Deborah F.Director
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001144204-18-003570 · tv483951_4.xml · derivative · entry 1 Aghib Deborah F. · CIK 0001727655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2025-01-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third on January 23, 2019, as to one-third on January 23, 2020 and as to the remaining one-third on January 23, 2021. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 20:45 UTC |
OAKES FRANK R.Director · President & CEO
|
GrantCommon Shares, without par value | 235,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-034655 · v469936_4.xml · nonDerivative · entry 1 OAKES FRANK R. · CIK 0001620188 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,467 F1 · shares: Shares issued under the issuer's Performance Share Plan. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 20:45 UTC |
MORSE DANIEL E.Director
|
GrantCommon Shares, without par value | 134,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-034654 · v469931_4.xml · nonDerivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,189 F1 · shares: Shares issued under the issuer's Performance Share Plan. Read SEC document |
| March 28, 2017 Filed Mar 29, 2017 12:00 UTC |
BAXTER GREGORY T.EVP, Corporate Development
|
GrantShare Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001144204-17-017153 · v462869_4.xml · derivative · entry 1 BAXTER GREGORY T. · CIK 0001620138 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2024-03-28 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third on March 23, 2018, as to one-third on March 23, 2019 and as to the remaining one-third on March 23, 2020. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 17:00 UTC |
Chun PaulDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001144204-17-016842 · v462721_4.xml · derivative · entry 1 Chun Paul · CIK 0001692037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2024-03-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 23, 2018 and as to the remaining one-third on September 23, 2018. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 17:00 UTC |
Che Tessie MDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001144204-17-016841 · v462720_4.xml · derivative · entry 1 Che Tessie M · CIK 0001380900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2024-03-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 23, 2018 and as to the remaining one-third on September 23, 2018. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 21:02 UTC |
SAMPAT MAYANK D.Director
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001144204-17-016847 · v462726_4.xml · derivative · entry 1 SAMPAT MAYANK D. · CIK 0001620136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2024-03-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 23, 2018 and as to the remaining one-third on September 23, 2018. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 21:02 UTC |
Olson Charles VDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001144204-17-016845 · v462725_4.xml · derivative · entry 1 Olson Charles V · CIK 0001663298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2024-03-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 23, 2018 and as to the remaining one-third on September 23, 2018. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 21:01 UTC |
MORSE DANIEL E.Director
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001144204-17-016844 · v462723_4.xml · derivative · entry 1 MORSE DANIEL E. · CIK 0001621331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2024-03-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 23, 2018 and as to the remaining one-third on September 23, 2018. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 21:01 UTC |
HILL DAVID LOUISDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001144204-17-016843 · v462722_4.xml · derivative · entry 1 HILL DAVID LOUIS · CIK 0001620224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2024-03-23 F1 · derivative.exercise_date: Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 23, 2018 and as to the remaining one-third on September 23, 2018. Read SEC document |
| January 12, 2017 Filed Jan 12, 2017 21:35 UTC |
OAKES FRANK R.Director · President & CEO
|
GiftCommon Shares, without par value | 40,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-002015 · v456838_4.xml · nonDerivative · entry 1 OAKES FRANK R. · CIK 0001620188 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,777 Read SEC document |
| December 20, 2016 Filed Dec 21, 2016 17:01 UTC |
Chun PaulDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001144204-16-140711 · v455476_4.xml · derivative · entry 1 Chun Paul · CIK 0001692037 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2023-12-20 F1 · derivative.exercise_date: Option grant under the 2013 Fixed Share Option Plan, which shall vest as to one-third on December 20, 2017, as to one-third on December 20, 2018 and as to the remaining one-third on December 20, 2019. Read SEC document |
| December 20, 2016 Filed Dec 21, 2016 17:04 UTC |
Che Tessie MDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001144204-16-140718 · v455481_4.xml · derivative · entry 1 Che Tessie M · CIK 0001380900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2023-12-20 F1 · derivative.exercise_date: Option grant under the 2013 Fixed Share Option Plan, which shall vest as to one-third immediately, as to one-third on December 20, 2017 and as to the remaining one-third on June 20, 2018. Read SEC document |
| December 20, 2016 Filed Dec 21, 2016 22:03 UTC |
HILL DAVID LOUISDirector
|
GrantShare Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001144204-16-140716 · v455480_4.xml · derivative · entry 1 HILL DAVID LOUIS · CIK 0001620224 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Shares · 2,500 shares Expires 2023-12-20 F1 · derivative.exercise_date: Option grant under the 2013 Fixed Share Option Plan, which shall vest as to one-third immediately, as to one-third on December 20, 2017 and as to the remaining one-third on June 20, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.